Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Predicting visual acuity deterioration and radiation-induced toxicities after brachytherapy for choroidal melanomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Predicting Visual Acuity Deterioration and Radiation-Induced Toxicities after Brachytherapy for Choroidal Melanomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Interventional Techniques to Management of Cancer-Related Pain: Clinical and Critical Aspects

    Research output: Contribution to journalReviewResearchpeer-review

  1. The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Joint tobacco smoking and alcohol intake exacerbates cancer risk in women- the Danish nurse cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Rare cause of spontaneous haemothorax: mediastinal and distant lymph node metastases from uveal melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Uveal melanoma (UM) is the most common intraocular malignancy in adults and shows a high rate of metastatic spread. As randomized clinical trials with immune checkpoint inhibitors (ICI) have not been performed in patients with metastatic UM, we analyzed the real-world outcomes in a nationwide population-based study. Clinical data of patients with UM were extracted from the Danish Metastatic Melanoma database, a nationwide database containing unselected records of patients diagnosed with metastatic melanoma in Denmark. Survival before (pre-ICI, n = 32) and after (post-ICI, n = 94) the approval of first-line treatment with ICI was analyzed. A partial response to first-line treatment was observed in 7% of patients treated with anti-programmed cell death protein (PD)-1 monotherapy and in 21% with combined anti-cytotoxic T lymphocyte antigen (CTLA)-4 plus anti-PD-1 therapy. Median progression-free survival was 2.5 months for patients treated in the pre-ICI era compared to 3.5 months in the post-ICI era (hazard ratio (HR) 0.43; 95% confidence interval (CI) 0.28-0.67; p < 0.001). The estimated one-year overall survival rate increased from 25.0% to 41.9% and the median overall survival improved from 7.8 months to 10.0 months, respectively (HR 0.52; 95% CI 0.34-0.79; p = 0.003). Thus, the introduction of ICI as first-line treatment appears to have significantly improved the real-world survival of patients with metastatic UM, despite relatively low response rates compared to cutaneous melanoma. With the lack of therapies proven effective in randomized trials, these data support the current treatment with ICI in patients with metastatic UM.

Original languageEnglish
JournalCancers
Volume11
Issue number10
ISSN2072-6694
DOIs
Publication statusPublished - 3 Oct 2019

ID: 58521057